YL-17231 not checked

Shanghai YingLi Pharmaceutical Co. Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“YL-17231 will be administered orally once daily in a continuous regimen”In the company’s words, NCT06096974 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors
Main trialPhase 1
“This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.”In the company’s words, NCT06096974 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumors

All 2439 drugs for Advanced Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Oct 2025 Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Phase 1Unknown Mar 2025 A Study of YL-17231 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow YL-17231

Following is part of Solo: you see every change to YL-17231 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in